Advertisement

Immunoliposomes

  • Sylvia K. E. MesserschmidtEmail author
  • Julia Beuttler
  • Miriam Rothdiener
Protocol
  • 2k Downloads
Part of the Springer Protocols Handbooks book series (SPH)

Abstract

In this chapter, we describe the generation of immunoliposomes by means of two different methods applying different scFv formats. The cloning strategies of these scFv variants possessing an additional cysteine residue for site-directted coupling are also presented in this chapter. Furthermore, a procedure for preparation and analysis of drug-loaded immunoliposomes is presented.

Keywords

Lipid Film Coupling Buffer PEGylated Liposome Sepharose CL4B Column scFv Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Iden DL, Allen TM (2001) In vitro and in vivo comparison of immunoliposomes made by conventional coupling technique with those made by a new post-insertion approach. Biochim Biophys Acta 1531:207–216Google Scholar
  2. Koning GA, Morselt HWM, Gorter A, Allen TM, Zalipsky S, Scherphof GL, Kamps JAAM (2003) Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res 20:1249–1257PubMedCrossRefGoogle Scholar
  3. Kontermann RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther 8:39–45PubMedGoogle Scholar
  4. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW (2003) Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 6:271–279PubMedCrossRefGoogle Scholar
  5. Marty C, Scheidegger P, Ballmer-Hofer K, Klemenz R, Schwendener RA (2001) Production of functionalized single-chain Fv antibody fragments to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Protein Expr Purif 21:156–164PubMedCrossRefGoogle Scholar
  6. Messerschmidt SK, Kolbe A, Müller D, Knoll M, Pleiss J, Kontermann RE (2008) Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling. Bioconjug Chem 19:362–369PubMedCrossRefGoogle Scholar
  7. Nobs L, Buchegger F, Gurny R, Allémann E (2004) Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 93:1980–1992PubMedCrossRefGoogle Scholar
  8. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC (2001) Tumor targeting using anti-HER2 immunoliposomes. J Control Release 74:95–113PubMedCrossRefGoogle Scholar
  9. Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196–205PubMedCrossRefGoogle Scholar
  10. Sapra P, Moase EH, Ma J, Allen TM (2004) Improved therapeutic responses in a xenograft model of human B lmyphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin Cancer Res 10:1100–1111PubMedCrossRefGoogle Scholar
  11. Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 5:189–204PubMedCrossRefGoogle Scholar
  12. Völkel T, Hölig P, Merdan T, Müller R, Kontermann RE (2004) Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 1663:158–166PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Sylvia K. E. Messerschmidt
    • 1
    Email author
  • Julia Beuttler
    • 1
  • Miriam Rothdiener
    • 1
  1. 1.Institute of Cell Biology and ImmunologyUniversity of StuttgartStuttgartGermany

Personalised recommendations